AXS-05 Reaches FDA Decision Deadline With April 30 PDUFA Date, Poised to Become Second-Ever Approved Drug for Alzheimer's Agitation
Axsome Therapeutics' AXS-05 faces its FDA verdict on April 30 for Alzheimer's disease agitation, backed by four Phase 3 trials but complicated by one failed study.
5 min read5 sources